Recent studies have shown that these novel agonists of TLR9 induced mucosal Th1 immune responses in mouse [25], increased the sensitivity of human non small cell lung cancer (NSCLC) cell lines to chemotherapy [26] and inhibited the growth of murine CT26 colon tumor, B16.F0 melanoma and human breast cancers in vivo [27]. Here, TLR9 is linked to non-small cell lung carcinoma.